Please assess the completion status of the following clinical trial:

Trial Title: AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria include:~1. Diagnosis type I Diabetes Mellitus for at least 12 months~2. Receiving treatment with multiple daily insulin injections or insulin pump therapy for at least 12 months~3. Fasting C-peptide concentration ≤8.5% (≤69 mmol/mol) at screening~4. BMI 18.5-35.0 kg/m2~Exclusion Criteria include:~1. known or suspected hypersensitivity to Investigational Medicinal Products~2. clinically significant concomitant disease or abnormal lab values~3. supine systolic BP outside range 95-140 mmHg and/or diastolic BP greater than 90 mmHg

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- AT247 (Type: EXPERIMENTAL): Single subcutaneous injection 0.3 U/Kg
- NovoRapid (Type: ACTIVE_COMPARATOR): Single subcutaneous injection 0.3 U/Kg
- Fiasp (Type: ACTIVE_COMPARATOR): Single subcutaneous injection 0.3 U/Kg

Based on this trial design, predict the completion outcome and termination type (if applicable).